Immune Checkpoint Inhibitor Therapy Tied to Cardiac Event Risk
Increased risks persist beyond six months for patients with lung cancer receiving PD1i and with malignant melanoma receiving CTLA-4i
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.